Dear Editor
We present the data of serial systemic immune inflammation indices (SSIIi) over four months in the setting of PCNS. The clinical details of this case were published previously [1]. The patient showed evidence of PCNS on discharge with persistent fatigue, brain fog, tiredness with a modified Rankin score of 3 at three months post-discharge [2]. His SSIIi over four months are shown in Fig. 1 (note the first SII (normal at 252)on 12/02/2020 was three weeks before the COVID-19 infection.).
Fig. 1.
Serial systemic immune inflmmatory indices (SSIIi) over a four months period in a case of Post Covid-19 Neurological Syndrome (PCNS).
Systemic immune inflammation index (SII) includes neutrophil, platelet and lymphocyte counts which comprehensively summarizes the interplay between the innate and adaptive immune system in COVID-19, cancer, stroke, venous sinus thrombosis and many other disorders. Each SSIIi peak was clinically correlated with an additional neurological or thromboembolic event in this case [1]. Shared pathobiology between stroke and COVID-19 associated neurological disorders are well described and likely to benefit from SSIIi in diagnosis, progress and prognosis of these global health problems [[3], [4], [5], [6], [7]]. We suggest SSIIi to be an excellent, easily available, universal biomarker for many neurological diosrders, in particular, stroke.
The emerging reports suggest that admission SII's clinical utility is a significant prognostic biomarker for survival in COVID-19 [8]. We believe the value of SSIIi is far higher than a single SII as demonstrated here. Given the pandemic's enormity, the routine reporting of SII in simple blood tests might provide extra, useful information universally.
References
- 1.Wijeratne T., Sales C.A., Crewther S.G., Nguyen V., Karimi L. First Australian case of good recovery of a COVID-19 patient with severe neurological symptoms post prolonged hospitalization. Cureus. 2020;12(9) doi: 10.7759/cureus.10366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Wijeratne T., Crewther S. Post-COVID 19 neurological syndrome (PCNS); a novel syndrome with challenges for the global neurology community. J. Neurol. Sci. 2020;419:117179. doi: 10.1016/j.jns.2020.117179. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Wijeratne T., Crewther S. COVID-19 and long-term neurological problems: challenges ahead with Post-COVID-19 Neurological Syndrome. Aust J. Gen. Pract. 2021;50 doi: 10.31128/AJGP-COVID-43. [DOI] [PubMed] [Google Scholar]
- 4.Wijeratne T., Gillard Crewther S., Sales C., Karimi L. COVID-19 pathophysiology predicts that ischemic stroke occurrence is an expectation, not an exception—a systematic review. Front. Neurol. 2021;11(1759) doi: 10.3389/fneur.2020.607221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Anrather J., Iadecola C. Inflammation and stroke: an overview. Neurotherapeutics. 2016;13(4):661–670. doi: 10.1007/s13311-016-0483-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Iadecola C., Anrather J. The immunology of stroke: from mechanisms to translation. Nat. Med. 2011;17(7):796–808. doi: 10.1038/nm.2399. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Iadecola C., Anrather J., Kamel H. Effects of COVID-19 on the nervous system. Cell. 2020;183(1) doi: 10.1016/j.cell.2020.08.028. 16–27.e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Fois A.G., Paliogiannis P., Scano V., Cau S., Babudieri S., Perra R., et al. The systemic inflammation index on admission predicts in-hospital mortality in COVID-19 patients. Molecules. 2020;25(23) doi: 10.3390/molecules25235725. [DOI] [PMC free article] [PubMed] [Google Scholar]